

S/N 10/665,990

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael A. Apicella et al. Art Unit : 1645
Serial No. : 10/665,990 Examiner : Padmavathi Baskar
Filed : September 19, 2003 Docket : 17023.031US1
Title : VACCINE AND COMPOSITIONS FOR THE PREVENTION AND
TREATMENT OF NEISSERIAL INFECTIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

An Information Disclosure Statement filing fee of \$180.00 is submitted herewith. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
Michael A. Apicella et al.
By their Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
St. Paul, MN 55111
952 876 4094

Date October 04, 2006

By 
Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8 I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 4 day of October, 2006.

Name Peter Malen

Signature 

Substitute for form 1449A/PTO and/or 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (Use as many sheets as necessary)

Complete if Known

Application Number	10/665,990
Filing Date	September 19, 2003
First Named Inventor	Michael A. Apicella
Group Art Unit	1645
Examiner Name	Padmavathi Baskar

Sheet 1 of 1

Attorney Docket No: 17023.031US1

US PATENT DOCUMENTS

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
	2003/0100071	May 29, 2003	Apicella et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document Number (Include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	International Search Report for International Application Serial Number PCT/US02/02881, (2003).
	International Search Report for International Application Serial Number PCT/US2004/022708, (2004).
	Barritt et al., "Antigenic and structural differences among six proteins II expressed by a single strain of <i>Neisseria gonorrhoeae</i> ", <i>Infect Immun.</i> , 55(9), 2026-2031 (1987).
	Cohen et al., "Human experimentation with <i>Neisseria gonorrhoeae</i> : Progress and goals", <i>J Infect Dis.</i> , 179, Suppl 2, S375-S379 (1999).
	Densen, "Interaction of complement with <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i> ", <i>Clin Microbiol Rev.</i> , 2, Suppl:S11-17 (1989).
	Edwards et al., " <i>Neisseria gonorrhoeae</i> elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells", <i>Infect Immun.</i> , 68(9), 5354-5363 (2000).
	Edwards et al., " <i>Neisseria gonorrhoeae</i> PLD directly interacts with Akt kinase upon infection of primary human, cervical epithelial cells", <i>Cell Microbiol.</i> , 8(8), 1253-1271 (2006).
	Thankavel et al., "Localization of a domain in the FimH adhesin of <i>Escherichia coli</i> type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection", <i>J Clin Invest.</i> , 100(5), 1123-1136 (1997).
	Zhang et al., "Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of <i>Streptococcus mutans</i> and protection against infection", <i>Infect Immun.</i> , 70(12), 6779-6787 (2002).

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-3445)

* Examiner: Initial if document considered, whether or not the citation is in accordance with MPEP § 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.